High-dose-rate interstitial brachytherapy for mobile tongue cancer: Influence of the non-irradiated period

Anticancer Research

Volumn 26, Issue 5 B, 2006, Pages 3933-3937

  Kakimoto, Naoya ^a,c   Inoue, Takehiro ^a   Inoue, Toshihiko ^a   Murakami, Shumei ^a   Furukawa, Souhei ^a   Yoshida, Ken ^a   Yoshioka, Yasuo ^a   Yamazaki, Hideya ^a   Tanaka, Eiichi ^a   Shimizutani, Kimishige ^b  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA DENTAL UNIVERSITY   (Japan)

^c OSAKA UNIVERSITY   (Japan)

Author keywords

High dose rate; Interstitial radiotherapy; Non irradiated period; Tongue carcinoma

Indexed keywords

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RADIATION DOSE; TONGUE CANCER;

ADULT; AGED; AGED, 80 AND OVER; BRACHYTHERAPY; HUMANS; MIDDLE AGED; RADIOTHERAPY DOSAGE; TONGUE NEOPLASMS; TREATMENT OUTCOME;

EID: 33750835092     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Mazeron JJ, Crook JM, Benck V, Marinello G, Martin M, Raynal M, Haddad E, Peynegre R, Le Bourgeois JP, Walop W and Pierquin B: Iridium 192 implantation of T1 and T2 carcinomas of the mobile tongue. Int J Radiat Oncol Biol Phys 19: 1369-1376, 1990.
2. Pernot M, Malissard L, Aletti P, Hoffstetter S, Forcard JJ and Bey P: Iridium-192 brachytherapy in the management of 147 T2N0 oral tongue carcinomas treated with irradiation alone: comparison of two treatment techniques. Radiother Oncol 23: 223-228, 1992.
3. Shibuya H, Hoshina M, Takeda M, Matsumoto S, Suzuki S and Okada N: Brachytherapy for stage I & II oral tongue cancer: an analysis of past cases focusing on control and complications. Int J Radiat Oncol Biol Phys 26: 51-58, 1993.
4. Matsuura K, Hirokawa Y, Fujita M, Akagi Y and Ito K: Treatment results of stage I and II oral tongue cancer with interstitial brachytherapy: maximum tumor thickness is prognostic of nodal metastasis. Int J Radiat Oncol Biol Phys 40: 535-539, 1998.
5. Lau HY, Hay JH, Flores AD and Threlfall WJ: Seven fractions of twice daily high dose-rate brachytherapy for node-negative carcinoma of the mobile tongue results in loss of therapeutic ratio. Radiother Oncol 39: 15-18, 1996.
6. Leung TW, Wong VY, Wong CM, Tung SY, Lui CM, Leung LC and O SK: High dose rate brachytherapy for carcinoma of the oral tongue. Int J Radiat Oncol Biol Phys 39: 1113-1120, 1997.
7. Kakimoto N, Inoue T, Inoue T, Murakami S, Furukawa S, Yoshida K, Yamazaki H, Tanaka E and Shimizutani K: Results of low- and high-dose-rate interstitial brachytherapy for T3 mobile tongue cancer. Radiother Oncol 68: 123-128, 2003.
8. Ihara N, Shibuya H, Yoshiura R, Oota S, Miura M and Watanabe H: Interstitial brachytherapy and neck dissection for Stage III squamous cell carcinoma of the mobile tongue. Acta Oncologica 44: 709-716, 2005.
9. Teshima T, Inoue T, Ikeda H, Murayama S, Furukawa S and Shimizutani K: Phase I/II study of high-dose rate interstitial radiotherapy for head and neck cancer. Strahlenther Onkol 168: 617-621, 1992.
10. Inoue T, Inoue T, Teshima T, Murayama, S, Shimizutani K, Fuchihata H and Furukawa S: Phase III trial of high and low dose rate interstitial radiotherapy for early oral tongue cancer. Int J Radiat Oncol Biol Phys 36: 1201-1204, 1996.
11. Inoue T, Inoue T, Yoshida K, Yoshioka Y, Shimamoto S, Tanaka E, Yamazaki H, Shimizutani K, Teshima T and Furukawa S: Phase III trial of high- vs. low-dose-rate interstitial radiotherapy for early mobile tongue cancer. Int J Radiat Oncol Biol Phys 57: 171-175, 2001.
12. Taylor JM, Withers HR and Mendenhall WM: Dose-time considerations of head and neck squamous cell carcinomas treated with irradiation. Radiother Oncol 17: 95-102, 1990.
13. Fowler JF and Lindstrom MJ: Loss of local control with prolongation in radiotherapy. Int J Radiat Oncol Biol Phys 23: 457-467, 1992.
14. Hansen O, Overgaard J, Hansen HS, Overgaard M, Hoyer M, Jorgensen KE, Bastholt L and Berthelsen A: Importance of overall treatment time for the outcome of radiotherapy of advanced head and neck carcinoma: dependency on tumor differentiation. Radiother Oncol 43: 47-51, 1997.
15. Overgaard J, Alsner J, Eriksen J, Horsman MR and Grau C: Importance of overall treatment time for the response to radiotherapy in patients with squamous cell carcinoma of the head and neck. Rays 25: 313-319, 2000.
16. Sobin LH and Wittekind C (eds.): UICC TNM Classification of Malignant Tumors. 6th ed. New York, John Wiley & Sons, Inc., 2002.
17. Overgaard J, Hjelm-Hansen M, Johansen LV and Andersen AP: Comparison of conventional and split-course radiotherapy as primary treatment in carcinoma of the larynx. Acta Oncol 27: 147-152, 1988.
18. Withers HR, Taylor JM and Maciejewski B: The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 27: 131-146, 1988.
19. Withers HR, Maciejewski B, Taylor JM and Hliniak A: Accelerated repopulation in head and neck cancer. Front Radiat Ther Oncol 22: 105-110, 1988.
20. Fowler JF, Tanner M, Bataini JP, Asselain B, Bernier J and Lave C: Further analysis of the time factor in squamous cell carcinoma of the tonsillar region. Radiother Oncol 19: 237-244, 1990.
21. Wilson GD: Tpot and head and neck cancer: where are we now? Anticancer Res 18: 4801-4805, 1998.
22. Alsner J, Hoyer M, Sorensen SB and Overgaard J: Interaction between potential doubling time and TP53 mutation: predicting radiotherapy outcome in squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 49: 519-525, 2001.